Sun Pharmaceutical Industries remained relatively resilient in an otherwise weak market after securing a favourable pricing agreement in the US, according to Reuters. The development is expected to reduce tariff-related concerns for the company for the next two years.
The agreement provides greater visibility to Sun Pharma’s US business at a time when Indian pharmaceutical companies are closely monitoring regulatory and trade-related developments.
The stock gained around 0.5% even as broader Indian markets declined. Investors will continue to track the company’s US operations and specialty-medicine business, which remain important drivers of its long-term growth.
